Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT04162834 Completed - Kidney Cancer Clinical Trials

Effect of Papaverine on Renal Artery Blood Flow Volume

Start date: November 21, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery.

NCT ID: NCT04154163 Completed - Ovarian Cancer Clinical Trials

Appropriate Dosing to Optimise Personalised Cancer Treatments

ADOPT
Start date: January 10, 2020
Phase:
Study type: Observational

This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted treatment with BRAF and MEK inhibitors.

NCT ID: NCT04134390 Completed - Old Age; Debility Clinical Trials

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

CABOMAYOR
Start date: February 17, 2020
Phase: Phase 2
Study type: Interventional

Aged fragile patients are not usually included in clinical trials and efficacy and tolerability of the different available treatments in this population are unknown. Conversely, ageing has been associated with a decrease in the efficacy of immune checkpoint inhibitors due to a decline in the effectiveness of the immune system (immunosenescence). In the Checkmate 025 trial comparing nivolumab with everolimus, the Hazard Ratio (HR) in patients older than 75 years old favoured everolimus, 1.23 (0.66-2.31). Thus, TKis might be a better treatment option for this population. However, the absence of data and concerns about possible secondary effects associated, can preclude clinicians to treat aged fragile patients with cabozantinib. A pilot phase II trial would help to have data on safety and efficacy of cabozantinib in this aged fragile population. In METEOR trial around 60% of patients reduced the dose of cabozantinib because of toxicity and tolerance problems. It is suspected that the efficacy of cabozantinib in the population to be included in this trial (aged and fragile) will be similar to that observed in CABOSUN trial (disease control rate around 75%). However, there is no information available in this group of patients. On the other hand, in the >75 years old subgroup within the METEOR trial, 37% discontinued due to adverse events, 85% needed dose reductions and median average daily dose was 33,6 mg. For this reason, the cabozantinib initial dose chosen for patients to be included in this study is 40 mg/day.

NCT ID: NCT04072224 Completed - Renal Tumor Clinical Trials

Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and Lung

Ablation
Start date: October 23, 2018
Phase:
Study type: Observational

Microwave thermal ablation (MO) is recognized as an alternative to surgery for the local-regional treatment of primary and secondary hepatic and renal tumors and for secondary pulmonary tumors in patients at anesthetic and/or surgical risk. Microwaves have a reputation for not producing reproducible ablation volumes with elliptical deformations and risks of over or under processing. The Covidien manufacturer offers a microwave system that guarantees more spherical and reproducible ablations: Emprint TM ablation system with Thermosphere TM technology (thermal control, field control, wavelength control). The investigators have 2 years of experience and therefore propose to carry out a first retrospective study, on a cohort of about fifty patients, whose objective will be to compare the volume of in vivo ablation one month after thermo-ablative treatment by microwave of a hepatic, renal or pulmonary tumour with the reference volume announced by the Covidien abacus manufacturer. Microwave ablation, which is much less studied, is less used because of the low reproducibility of necrosis volumes. The Covidien manufacturer offers a system that allows ablation volumes that are supposed to be reproducible, which attracted the Nîmes University Hospital during the call for tenders. To the investigator's knowledge, there are no studies that have evaluated the actual volume of ablation by this system.

NCT ID: NCT04021238 Completed - Kidney Cancer Clinical Trials

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

Start date: October 7, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with suspected kidney cancer with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT03907657 Completed - Clinical trials for Kidney Disease, Chronic

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

CEUS-VHL
Start date: September 23, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with Von-Hippel Lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT03887091 Completed - Prostate Cancer Clinical Trials

Personal Web Page In Clinical Trial Participant Education

Start date: July 21, 2014
Phase: N/A
Study type: Interventional

This research study is evaluating the effectiveness of video and web-based communication in clinical research compared to standard practices.

NCT ID: NCT03852030 Completed - Prostate Cancer Clinical Trials

Mind-Body Health in Uro-Oncology: Research Study

Start date: July 2012
Phase: N/A
Study type: Interventional

In this study, the researchers will examine the effects of post-mindfulness intervention email and text messages to promote maintenance of intervention effects over time in a uro-oncology sample (clinically localized prostate, kidney, and bladder cancer) of patients and spouses.

NCT ID: NCT03841149 Completed - Clinical trials for Chronic Kidney Diseases

Volume 3D_US Kidney

VolUS3D
Start date: June 29, 2020
Phase:
Study type: Observational

The purpose of this study is to measure the volume of the kidney and tumors using 3D-US acquisition and to correlate these measurements to contrast-enhanced CT or MRI.

NCT ID: NCT03666104 Completed - Clinical trials for Renal Cell Carcinoma

Using Virtual Reality (VR) Models for Preoperative Planning - Mount Sinai

Start date: August 21, 2018
Phase: N/A
Study type: Interventional

A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic partial nephrectomy) and improved patient care.